Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Lymphoma, B-Cell Clinical Trial

Official title:

A Phase 1B/2 Randomized, Multicenter, Open-Label Study Of Iberdomide (CC-220) In Combination With Polatuzumab Vedotin Plus Rituximab Or Tafasitamab Or Rituximab Plus Chemotherapy For Subjects With Relapsed Or Refractory Aggressive B-Cell Lymphoma

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04882163
• Other study ID #: CC-220-DLBCL-002
• Secondary ID: 2020-005333-32
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• Start date: October 10, 2021
• Est. completion date: April 7, 2029

Study information

• Verified date: September 2021
• Source: Celgene
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1b/2 randomized study of Iberdomide (CC-220) added to 3 different combination regimens (polatuzumab vedotin plus rituximab (Cohort A), tafasitamab (Cohort B), rituximab plus gemcitabine and platinum-based chemotherapy (Cohort C)) for participants with relapsed or refractory aggressive B-cell lymphoma (R/R a-BCL). All 3 cohorts will be open for enrollment at study start. Part 1 (dose escalation) will be followed by Part 2 (dose expansion), in which participants will be randomized to one of three cohorts, with CC-220 at the recommended Phase 2 Dose in combination with the Cohorts A, B and C treatment that is compared to their individual standard of care regimen.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 7, 2029
• Est. primary completion date: April 8, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants must satisfy the following criteria to be enrolled in the study:

1. Participant is = 18 years of age at the time of signing the informed consent form (ICF).

2. Participant has histologically confirmed (per local evaluation) diagnosis of, aggressive B-cell lymphoma (a-BCL) according to 2016 WHO classification among the following subtypes:

1. Diffuse large B-cell lymphoma (DLBCL), Not otherwise specified (NOS) including Germinal center B-cell and Activated B-cell types;

2. High-grade B-cell lymphoma, with MYC and B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangements;

3. Primary mediastinal (thymic) large B-cell lymphoma (PMBCL);

4. Primary cutaneous DLBCL-leg type;

5. Anaplastic lymphoma kinase positive (ALK+) large B-cell lymphoma;

6. Epstein Barr virus positive (EBV+) DLBCL, NOS;

7. Grade 3b Follicular lymphoma (FL).

3. Participants must have relapsed or refractory disease after at least 2 prior lines of therapy including Rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP)-like regimen OR after one prior line of standard therapy and being not eligible for autologous stem cell transplant (ASCT); participants previously treated with CAR-T therapy can be enrolled.

4. Participant must have measurable disease defined by at least one FDG-avid lesion for FDGavid-subtype and one bi-dimensionally measurable (> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification (Cheson, 2014).

5. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

6. Participant must have the following laboratory values:

1. Absolute neutrophil count (ANC) = 1.5 x 109/L or = 1.0 x 109/L in case of documented bone marrow involvement (> 50% or tumor cells), without growth factor support for 7 days (14 days if pegylated granulocyte-colony stimulating factor (peg-G-CSF))

2. Hemoglobin = 8 g/dL

3. Platelets = 75 x 109/L or = 50 x 109/L in case of documented bone marrow involvement (> 50% or tumor cells), without transfusion for 7 days

4. Aspartate aminotransferase / serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase / serum glutamic pyruvic transaminase (ALT/SGPT) = 2.5 x ULN except in the case of documented liver involvement by lymphoma, where ALT/SGPT and AST/SGOT must be = 5.0 x ULN.

5. Serum total bilirubin = 2.0 mg/dL (34 µmol/L) except in cases of Gilbert syndrome, then = 5.0 mg/dL (86 µmol/L)

6. Estimated serum creatinine clearance of = 50 mL/minute using the modification of diet in renal disease formula.

7. All participants must:

1. Have an understanding that the study drug could have a potential teratogenic risk.

2. Agree to follow all requirements defined in the Pregnancy Prevention Program for CC-220 Pregnancy Prevention Plan for Participants in Clinical Trials.

8. A female of childbearing potential (FCBP) must:

a. Have two negative pregnancy tests as verified by the investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study therapy.

9. Male participants must:

1. Practice true abstinence (which must be reviewed on a monthly basis and source documented) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study.

Exclusion Criteria:

• The presence of any of the following will exclude a participant from enrollment:

1. Participant has any significant medical condition, active infection (including SARS-CoV-2 suspected or confirmed), laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.

a. In the case of prior SARS-CoV-2 infection, symptoms must have completely resolved

2. Participant has any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study.

3. Participant has any other subtype of lymphoma.

4. Participant has received systemic anti-cancer treatment, CAR-T or any T-cell targeting treatment (approved or investigational) = 5 half-lives or 4 weeks prior to starting CC-220, whichever is shorter.

5. Participant has received prior therapy with a Cereblon-modulating drug (eg, lenalidomide, avadomide) = 4 weeks prior to starting CC-220.

6. Participant has persistent diarrhea or malabsorption = Grade 2 (NCI-CTCAE v5.0), despite medical management.

7. Participant has peripheral neuropathy = Grade 2 (NCI CTCAE v5.0).

8. Participant is on chronic systemic immunosuppressive therapy or corticosteroids.

9. Participant has impaired cardiac function or clinically significant cardiac disease.

10. Participant had major surgery = 2 weeks prior to starting CC-220.

11. Participant has known seropositivity for or active viral infection with human immunodeficiency virus (HIV).

12. Participant has known chronic active hepatitis B

13. Participant has history of other malignancy, unless being free of the disease for = 3 years prior to starting study drug; exceptions to the = 3-year time limit include history of the following:

1. Localized non-melanoma skin cancer

2. Carcinoma in situ of the cervix

3. Carcinoma in situ of the breast

4. Incidental histologic finding of prostate cancer (T1a or T1b as per Tumor Node Metastasis [TNM] staging system) or prostate cancer that has been treated with curative intent.

14. Participant has current treatment with strong CYP3A4/5 modulators.

15. Participant has known hypersensitivity to any component of planned combination medications in the regimen.

16. Participant has known allergy to thalidomide, pomalidomide, lenalidomide or avadomide.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell

Intervention

Drug:
• CC-220
CC-220
• Polatuzumab vedotin
Polatuzumab vedotin
• Rituximab
Rituximab
• Tafasitamab
Tafasitamab
• Gemcitabine
Gemcitabine
• Cisplatin
Cisplatin
• Dexamethasone
Dexamethasone
• Bendamustine
Bendamustine
• Lenalidomide
Lenalidomide

Locations

Country	Name	City	State
Austria	Medizinische Universität Graz	Graz
Austria	Universitätsklinikum St. Pölten	Sankt Pölten
Belgium	Cliniques Universitaires Saint-Luc	Brussels
Belgium	Hôpital de Jolimont	La Louvière
Belgium	H.-Hartziekenhuis Roeselare-Menen vzw	Roeselare
France	EDOG - Institut Bergonie - PPDS	Bordeaux
France	Hôpital François Mitterand	Dijon
France	Centre Hospitalier Lyon Sud	Lyon
France	EDOG - Institut Claudius Regaud - PPDS	Toulouse
France	Gustave Roussy	Villejuif CEDEX
Korea, Republic of	Asan Medical Center	Seoul
Korea, Republic of	Samsung Medical Center	Seoul
Korea, Republic of	Seoul National University Hospital	Seoul
Spain	Hospital Universitario Germans Trias i Pujol	Badalona
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Complejo Asistencial Universitario de Salamanca - H. Clinico	Salamanca
Spain	Hospital Universitario Virgen del Rocio - PPDS	Sevilla
Taiwan	Taipei Veterans General Hospital	Beitou District, Taipei City
Taiwan	Taichung Veterans General Hospital	Taichung
Taiwan	National Taiwan University Hospital	Taipei, Zhongzheng Dist.
United Kingdom	Beatson West of Scotland Cancer Centre	Glasgow Scotland
United Kingdom	Royal Liverpool University Hospital	Liverpool
United Kingdom	Nottingham University Hospitals NHS Trust	Nottingham
United Kingdom	University Hospital Southampton NHS Foundation Trust - Southampton General Hospital	Southampton
United States	University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Avera Cancer Institute	Sioux Falls	South Dakota

Sponsors (1)

Lead Sponsor	Collaborator
Celgene

Countries where clinical trial is conducted

United States,  Austria,  Belgium,  France,  Korea, Republic of,  Spain,  Taiwan,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose (MTD)	Frequency of dose limiting toxicities (DLT) to define MTD of CC- 220 in combination with polatuzumab vedotin plus rituximab or tafasitamab or rituximab plus chemotherapy in subjects with R/R a-BCL.	During the First cycle (each cycle is 28 days)
Primary	Recommended Phase 2 Dose (RP2D)	Frequency of dose limiting toxicities (DLT) to establish the RP2D of CC- 220 in combination with polatuzumab vedotin plus rituximab or tafasitamab or rituximab plus chemotherapy in subjects with R/R a-BCL.	During the First cycle (each cycle is 28 days)
Primary	Best Overall Response Rate (ORR)	The proportion of participants with best overall response achieved during the study as either Complete Response or Partial Response before subsequent anti-lymphoma therapy.	Up to 7 years
Secondary	Incidence of Adverse Events (AEs)	An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.	From enrollment until at least 28 days after last dose of study treatment
Secondary	Best ORR- Part 1	The proportion of participants with best overall response achieved during the study as either Complete Response or Partial Response before subsequent anti-lymphoma therapy.	Up to 6 years
Secondary	Complete Response Rate (CRR)- Part 2	The proportion of participants experiencing Complete Response before receiving any subsequent anti-lymphoma therapy.	Up to 7 years
Secondary	Time to Response (TRR)- Part 2	The time from entry to the study (enrollment date for Part 1 and randomization date for Part 2) to the date of first documented response (= PR).	Up to 7 years
Secondary	Duration of Response (DOR)- Part 2	The time from the earliest date of documented response (= PR) to the first occurrence of relapse or progression.	Up to 7 years
Secondary	Progression-free Survival (PFS)- Part 2	The time from entry to the study (enrollment date for Part 1 and randomization date for Part 2) to the first occurrence of disease progression or death from any cause.	Up to 7 years
Secondary	Overall Survival (OS)- Part 2	The time from entry to the study (enrollment date for Part 1 and randomization date for Part 2) to death from any cause.	Up to 7 years
Secondary	Pharmacokinetics (PK) - Cmax	Observed maximum CC-220 serum concentration	Up to 4 weeks
Secondary	EORTC QLQ-C30 - Part 2	European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30) consists of 30 questions incorporated into five functional domains (physical, role, cognitive, emotional, and social), nine symptom scales (fatigue, pain, nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a single global QoL/global health status score.	Up to 7 years
Secondary	FACT-Lym LymS - Part 2	Functional Assessment of Cancer Therapy-Lymphoma Lymphoma subscale (FACT-Lym LymS) is a 15-item subscale that addresses health-related quality of life symptoms for Non-Hodgkin's lymphoma participants (eg, swelling, night sweats). The FACT instruments use a 5-point intensity type of rating scale (from "not at all" to "very much").	Up to 7 years
Secondary	FACT/GOG-NTX-4 - Part 2	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity 40-item questionnaire (FACT/GOG-NTX-4) is a 4-item peripheral neuropathy subscale used to differentiate between participants with and without treatment-related neurotoxicity. The FACT instruments use a 5-point intensity type of rating scale (from "not at all" to "very much").	Up to 7 years
Secondary	EQ-5D-5L - Part 2	EQ-5D-5L has 2 components: a descriptive system and a visual analogue scale (VAS). The instrument's descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.	Up to 7 years